Effect of Sarcopenia and Frailty on Rocuronium Pharmacodynamics in Geriatric Patients

Konya Meram State Hospital100 enrolled

Overview

This prospective observational study aims to evaluate whether sarcopenia and frailty affect the pharmacodynamic profile of rocuronium in geriatric patients undergoing elective surgery under general anesthesia.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Sarcopenia Frailty Neuromuscular Blockade Rocuronium Pharmacodynamics

Eligibility

Sex: ALLMin age: 65 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Scheduled to undergo elective surgery under general anesthesia requiring endotracheal intubation * Planned use of rocuronium for neuromuscular blockade * Quantitative neuromuscular monitoring planned during anesthesia * American Society of Anesthesiologists physical status I-III * Ability to provide written informed consent * Completion of preoperative frailty and sarcopenia assessment Exclusion Criteria: * Emergency surgery * Known neuromuscular disease * History of allergy or contraindication to rocuronium, sugammadex * Severe hepatic insufficiency * Severe renal insufficiency * Use of drugs known to significantly affect neuromuscular transmission * Preoperative mechanical ventilation or intensive care unit admission * Inability to perform a frailty or sarcopenia assessment * Patients in whom quantitative neuromuscular monitoring cannot be properly performed * Refusal to participate in the study

Locations (1)

Betul Kozanhan

Konya, Turkey (Türkiye)

Outcomes

Primary Outcomes

Rocuronium onset time

Time from intravenous administration of rocuronium to disappearance of all train-of-four responses, defined as train-of-four count 0, measured using quantitative neuromuscular monitoring

Time frame: Perioperative/Periprocedural - during anesthesia induction

Secondary Outcomes

Time from train-of-four count 0 to train-of-four count 2

Time elapsed from achievement of train-of-four count 0 after the initial rocuronium dose to recovery of train-of-four count 2, recorded in minutes and measured using quantitative neuromuscular monitoring.

Time frame: From achievement of train-of-four count 0 after the initial rocuronium dose until recovery of train-of-four count 2 during surgery

Time to train-of-four ratio 0.9 after sugammadex administration

Time from sugammadex administration to recovery of train-of-four ratio to 0.9, measured using quantitative neuromuscular monitoring.

Time frame: From sugammadex administration until recovery of train-of-four ratio to 0.9 at the end of surgery

Total rocuronium dose

Total dose of rocuronium administered during anesthesia

Time frame: From anesthesia induction until the end of surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.